Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a significant licensing agreement with German healthcare giant Bayer. Under the terms of this agreement, Joincare has obtained development, commercialization, and manufacturing rights to Bayer’s small-molecule inhibitor in the respiratory field within China. The financial specifics of the deal were not disclosed.
The product in question is an innovative oral drug designed for the treatment of chronic obstructive pulmonary disease (COPD). It operates by inhibiting the activity of prolyl endopeptidase (PREP), thereby preventing the production of inflammatory mediators associated with COPD. The drug has successfully completed Phase I clinical trials in Europe, marking a step forward in the treatment of this respiratory condition.- Flcube.com
